Clinical Nephrology, Volume 104 (2025) - November (310 - 317)

The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism

Eiichi Sato1, Miyako Urata1, Shohei Sato1, Takao Ono1, Manaka Degawa1, Hongmei Lu1, Mayumi Nomura1, Daisuke Matsumura1, Noriaki Moriyama1, Mayuko Amaha1, Tsukasa Nakamura2
1 Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Matsudo, and 2 Department of Nephrology, Kashiwa Forest Clinic, Kashiwa, Japan

     

 

DOI 10.5414/CN111695

Abstract

Aims: No English-language research papers have reported on the clinical use of upacicalcet, a novel intravenous calcimimetic agent for the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. Therefore, this study aimed to investigate the outcomes of switching from etelcalcetide to upacicalcet.
Materials and methods: The subjects included 37 hemodialysis patients with SHPT treated with etelcalcetide before switching to upacicalcet. This study was a single-center retrospective study conducted in Japan. Serum levels of corrected calcium (Ca), phosphorus (P), intact parathyroid hormone (iPTH), and the dose of maxacalcitol were assessed at 3 and 6 months after switching to upacicalcet.
Results: As a result of the switch from etelcalcetide to upacicalcet, the serum corrected Ca level remained unchanged, from 8.9 ± 0.6 to 9.1 ± 0.7 mg/dL (p = 0.104) at 3 months and to 9.0 ± 0.6 mg/dL (p = 0.197) at 6 months. Meanwhile, the serum P level decreased from 6.3 ± 1.5 to 5.8 ± 1.5 mg/dL (p = 0.069) at 3 months and to 5.9 ± 1.9 mg/dL (p = 0.039) at 6 months. The iPTH level increased slightly, from 153.8 ± 100.3 pg/mL to 176.4 ± 124.6 pg/mL (p = 0.337) at 3 months and to 206.5 ± 168.7 pg/mL (p = 0.017) at 6 months. Multiple regression analysis revealed that the change in iPTH was related to the change in P levels.
Conclusion: These findings suggested that upacicalcet may be a useful option for managing serum P levels in hemodialysis patients with SHPT.

Author Details

Authors

Departments

  • 1 Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Matsudo, and
  • 2 Department of Nephrology, Kashiwa Forest Clinic, Kashiwa, Japan

Address

Eiichi Sato, MD, PhD
380 Shin-Matsudo 1-chome
Matsudo City, Chiba Prefecture, Japan
Email: [email protected]

Log in for Subscribers

Citation

Eiichi Sato, Miyako Urata, Shohei Sato, Takao Ono, Manaka Degawa, Hongmei Lu, Mayumi Nomura, Daisuke Matsumura, Noriaki Moriyama, Mayuko Amaha, Tsukasa Nakamura. The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism
. Clin Nephrol. 2025; 104: 310-317. doi: 10.5414/CN111695. Pubmed: https://pubmed.ncbi.nlm.nih.gov/40833047/; PMID: 40833047.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart